Overall, our results demonstrated that, despite a lack of anti-tumoral efficacy of mifamurtide treatment against aggressive and metastatic OS tumor cells, mifamurtide efficacy can be potentiated by the administration of an IL-10 blocking antibody. This evidence concerns the gene IL10 and neoplasm.